Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)
NCT ID: NCT05060107
Last Updated: 2021-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
10 participants
INTERVENTIONAL
2021-10-05
2023-10-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
NCT06466850
Intra-articular Injection of UC-MSC Exosome in Knee Osteoarthritis
NCT06431152
Clinical Efficacy of Exosome in Degenerative Meniscal Injury
NCT05261360
Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA
NCT02351011
Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).
NCT04893174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group - sEVs
Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.
Exosomes (sEVs)
Exosomes 3-5x10e11 particles/dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exosomes (sEVs)
Exosomes 3-5x10e11 particles/dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Knee OA Kellgren-Lawrence grade II to III
* Chondromalacia grade I to III
* Stable joint
Exclusion Criteria
* Local infection
* Neoplasia
* Joint replacement
* Recent use of local steroids
* BMI \> 30
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Francisco Espinoza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francisco Espinoza
Medical Chieff Officer, Regenero / C4C
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C4C060921
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.